Gilead Sciences, Inc. (GILD) Shares Bought by Dempze Nancy E

Dempze Nancy E increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 9.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 11,420 shares of the biopharmaceutical company’s stock after buying an additional 969 shares during the period. Gilead Sciences accounts for about 1.6% of Dempze Nancy E’s holdings, making the stock its 23rd largest position. Dempze Nancy E’s holdings in Gilead Sciences were worth $903,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the company. Cypress Capital Management LLC WY acquired a new position in shares of Gilead Sciences during the second quarter worth about $2,731,000. Rock Point Advisors LLC acquired a new position in shares of Gilead Sciences during the second quarter worth about $2,171,000. Atlas Brown Inc. boosted its position in shares of Gilead Sciences by 47.3% in the second quarter. Atlas Brown Inc. now owns 7,967 shares of the biopharmaceutical company’s stock worth $665,000 after buying an additional 2,560 shares in the last quarter. Eliot Finkel Investment Counsel LLC boosted its position in shares of Gilead Sciences by 93.2% in the second quarter. Eliot Finkel Investment Counsel LLC now owns 39,230 shares of the biopharmaceutical company’s stock worth $3,273,000 after buying an additional 18,920 shares in the last quarter. Finally, Waverton Investment Management Ltd boosted its position in shares of Gilead Sciences by 0.5% in the second quarter. Waverton Investment Management Ltd now owns 895,271 shares of the biopharmaceutical company’s stock worth $74,684,000 after buying an additional 4,776 shares in the last quarter. 74.19% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) opened at 66.36 on Monday. The company has a 50-day moving average of $72.26 and a 200 day moving average of $75.71. Gilead Sciences, Inc. has a one year low of $65.38 and a one year high of $103.10. The company has a market cap of $86.93 billion, a P/E ratio of 6.68 and a beta of 1.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.61 by $0.09. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The company earned $7.30 billion during the quarter, compared to the consensus estimate of $7.16 billion. During the same quarter in the prior year, the firm earned $3.32 earnings per share. The firm’s revenue was down 13.9% compared to the same quarter last year. Equities research analysts predict that Gilead Sciences, Inc. will post $8.88 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Thursday, March 16th will be given a dividend of $0.52 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 annualized dividend and a dividend yield of 3.13%. Gilead Sciences’s dividend payout ratio is currently 18.91%.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Dempze Nancy E” was published by sleekmoney and is owned by of sleekmoney. If you are accessing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The correct version of this piece of content can be read at http://sleekmoney.com/gilead-sciences-inc-gild-shares-bought-by-dempze-nancy-e/1657601.html.

A number of equities analysts have issued reports on the stock. Maxim Group reissued a “hold” rating on shares of Gilead Sciences in a report on Sunday, November 6th. Cowen and Company set a $120.00 price target on Gilead Sciences and gave the company a “buy” rating in a report on Sunday, October 23rd. Piper Jaffray Companies reaffirmed a “hold” rating and set a $95.00 price target (down previously from $102.00) on shares of Gilead Sciences in a report on Wednesday, February 8th. Jefferies Group LLC cut their price target on Gilead Sciences from $83.00 to $83.00 and set a “neutral” rating on the stock in a report on Wednesday, February 8th. Finally, BMO Capital Markets reaffirmed a “market perform” rating and set a $88.00 price target on shares of Gilead Sciences in a report on Friday, January 13th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, fourteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $88.94.

In related news, Director John W. Madigan sold 105,000 shares of the stock in a transaction on Friday, November 18th. The shares were sold at an average price of $74.86, for a total transaction of $7,860,300.00. Following the completion of the transaction, the director now owns 121,761 shares in the company, valued at $9,115,028.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John C. Martin sold 73,337 shares of the stock in a transaction on Tuesday, January 3rd. The stock was sold at an average price of $73.59, for a total transaction of $5,396,869.83. Following the transaction, the insider now owns 3,204,433 shares of the company’s stock, valued at approximately $235,814,224.47. The disclosure for this sale can be found here. 1.40% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/gilead-sciences-inc-gild-shares-bought-by-dempze-nancy-e/1657601.html

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *